Milnacipran for fibromyalgia.
Copyright policy )Milnacipran for fibromyalgia.
(1) Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). (2) Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. (3) Complete results of phase 3 trials have not yet been published. Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia.
Cyclopropanes, Canada, Clinical Trials as Topic, Fibromyalgia, Adrenergic Uptake Inhibitors, United States Food and Drug Administration, Pain, Antidepressive Agents, United States, Treatment Outcome, Humans, Drug Approval, Selective Serotonin Reuptake Inhibitors
Cyclopropanes, Canada, Clinical Trials as Topic, Fibromyalgia, Adrenergic Uptake Inhibitors, United States Food and Drug Administration, Pain, Antidepressive Agents, United States, Treatment Outcome, Humans, Drug Approval, Selective Serotonin Reuptake Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!